11 April 2023 - PHARMAC has announced the funding of risdiplam (Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet eligibility criteria from 1 May 2023.

PHARMAC understands that there are still people who would like to see wider criteria for funded access to spinal muscular atrophy treatments, including for those who are aged over 18 years at the time they start treatment. PHARMAC is actively considering this, having taken advice from its expert advisors on the Rare Disorders Advisory Committee in March 2023.

Read PHARMAC press release